Profossor RONG YU (Ph.D)
Recent research interests
I am mainly engaged in the structure, function and drug discovery studies from nature macromolecule and biopharmaceuticals manufactured by biotechnology methods.
1. DNA recombinant medicine
This study relates to the development of various recombinant DNA technology and high performance purification scheme for biopharmaceuticals. These projects usually involve construction, expression and purification of novel recombinant medicine. The gene recombinant separation technique makes a key success in modern biopharmaceutical. The techniques of separation and purification these proteins take important position in gene engineering.
2. Biochemical medicine and Microbial medicine
The objective of this project is to develop fast and efficient large scale biochemical isolation technology that will enable a high recovery of products. Process integration will be performed by combination of cell disruption, membrane separation and various chromatography.
3.The protein engineering therapeutics design
This research is aimed to develop new biotech drugs. The protein engineering technique has become an effective stratagem to improve variant properties of therapeutic proteins, including enhanced thermo stability, bioactive specify, targeted delivery, decrease in immunity and improving pharmacokinetics. Rational protein engineering is according to the hypothesis driven manipulation of protein sequence and/or composition. Biopharmaceuticals are now entering the third stage of product development in which true lead optimization to modulate the physical, chemical and biological properties of proteins is possible. Rational optimization of proteins as drugs makes a key success in modern biopharmaceutical. The controlled manipulation of the physical, chemical and biological properties of proteins enabled by structure-based simulation is now being used to refine established rational engineering approaches and to advance new strategies. These methods provide clear, hypothesis driven routes to solve problems that plague many proteins and to create novel mechanisms of action. An increasing number of engineered protein therapeutics are currently being developed, tested in clinical trials and marketed for use.
(1) Yaqiong Li，Xiunan Li (*) ，Chao Chen，Dawei Zhao，Zhiguo Su，Guanghui, Ma， Rong Yu (*) , Sol–gel transition characterization of thermosensitive hydrogels based on water mobility variation provided by low field NMR，Journal of Polymer Research， 2017.2.24， 24（25）
(2)Li Yaqiong，Li Xiunan (*)，Chen Chao，Zhao Dawei，Su Zhiguo，Ma Guanghui， Yu Rong(*) , A rapid, non-invasive and non-destructive method for studying swelling behavior and microstructure variations of hydrogels，Carbohyd rate Polymers，2016.10.20，151：1251~1260
(3) Cai Yingting，Bao Jingxiao，Lao Xingzhen(*) ，Zheng Heng，Chen Jianhua， Yu Rong(*), Computational design, functional analysis and antigenic epitope estimation of a novel hybrid of 12 peptides of hirudin and reteplase，Journal of Molecular Modeling， 2015.9.01， 21（9）
(4) Zhang Chun，Liu Yongdong(*)，Zhao Dawei，Li Xiunan, Yu Rong(*) ,Su Zhiguo, Facile purification of Escherichia coli expressed tag-free recombinant human tumor necrosis factor alpha from supernatant，Protein Expression and Purification， 2014.3.01，95：195~203
(5) Gao Ling，Zhang Chun，Li Lingling，Liang Lan，Deng Xuan，Wu Wutong，Su Zhiguo， Yu Rong(*), Construction, Expression and Refolding of a Bifunctional Fusion Protein Consisting of C-Terminal 12-Residue of Hirudin-PA and Reteplase，Protein Journal， 2012.4.01，31（4）：328~336
(6)Xiang Silong，Ma Yuyuan(*) ，Yan Qipo，Lv Maomin，Zhao Xiong，Yin Huiqiong，Zhang Nian，Jia Junting， Yu Rong(*)，Zhang, Jingang， Co nstruction and characterization of an infectious replication competent clone of porcine endogenous retrovirus from Chinese miniature pigs， Virology Journal，2013.7.9，10
Zhang ZenglanLi ..QiWang
8.Zhang Chun, Yu Rong ZenglanLi, CuiFeng, Qi Wang,Yongdong Liu, Zhiguo Su Development of long-acting ciliary neurotrophic factor by site-specific conjugation with different-sized polyethylene glycols and transferrin International Journal of Pharmaceutics
2017, 529(1–2), 275-284